-0.004 (-2.99%)
Range 0.122 - 0.138   (13.11%)
Open 0.131
Previous Close 0.134
Buy Price -
Buy Volume 30
Sell Price -
Sell Volume 10
Volume 1,594,208
Value -
Measurement Type Value
EPS (USD) -0.182
Trailing EPS (USD) -0.13
NAV (USD) 0.304
Cash In Hand (USD) 0.311
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 0.658
Price / Cash In Hand 0.644
Issued & Paid-up Shares 145,638,000
Treasury Shares -
Market Cap (M) 29.128
Par Value (USD) n.a.
Beta - 75 Days 0.89
R-Squared - 75 Days(%) 3.16
Beta - 500 Days 1.052
R-Squared - 500 Days(%) 7.13
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 22 Jan 2022 04:59.
Data powered by
View All Events


Advaxis, Inc. is a clinical development-stage company. The Company is a biotechnology company with the focus to develop safe and effective immunotherapies for cancer and infectious diseases. These immunotherapies are based on a platform technology under license from the University of Pennsylvania (Penn), that utilizes live attenuated Listeria monocytogenes (Lm), bioengineered to secrete antigen/adjuvant fusion proteins. These Lm strains use a fragment of the protein listeriolysin (LLO), fused to a tumor associated antigen (TAA) or other antigen of interest. In addition, the Company has developed immunotherapies for prostate cancer and HER2 overexpressing cancers (such as breast, gastric and other cancers in humans and for osteosarcoma in canines).